{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:46:58Z","timestamp":1791704818069,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031935","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["M057"],"award-info":[{"award-number":["M057"]}],"id":[{"id":"10.13039\/100031935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tranon.2026.102891","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:34:34Z","timestamp":1789421674000},"page":"102891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reversing sarcopenia with megestrol acetate ameliorates systemic inflammation and improves survival in NSCLC"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4662-6928","authenticated-orcid":false,"given":"Yamin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6131-7209","authenticated-orcid":false,"given":"Xiaochi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102891_bib0001","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced non squamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102891_bib0002","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 investigators, Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102891_bib0003","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"IMpower133 Study Group, first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102891_bib0004","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five year outcomes with Pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102891_bib0005","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","article-title":"Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"suppl 5","key":"10.1016\/j.tranon.2026.102891_bib0006","doi-asserted-by":"crossref","first-page":"990S","DOI":"10.1093\/jn\/127.5.990S","article-title":"Sarcopenia: origins and clinical relevance","volume":"127","author":"Rosenberg","year":"1997","journal-title":"J. Nutr."},{"issue":"12","key":"10.1016\/j.tranon.2026.102891_bib0007","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/JTO.0000000000000690","article-title":"Prognostic significance of CT-determined sarcopenia in patients with small-cell lung cancer","volume":"10","author":"Kim","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102891_bib0008","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102891_bib0009","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age (Omaha) Ageing"},{"key":"10.1016\/j.tranon.2026.102891_bib0010","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1634\/theoncologist.2016-0066","article-title":"The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature","volume":"21","author":"Rier","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2026.102891_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106907","article-title":"Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: a systematic review and metaanalysis","volume":"88","author":"Wang","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102891_bib0012","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.autrev.2017.12.005","article-title":"Skeletal muscle cells actively shape (auto)immune responses","volume":"17","author":"Afzali","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"14","key":"10.1016\/j.tranon.2026.102891_bib0013","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.3390\/cancers15143592","article-title":"Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: correlation with sarcopenia","volume":"15","author":"Tenuta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tranon.2026.102891_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.molimm.2004.07.033","article-title":"Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells","volume":"42","author":"Screpanti","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.tranon.2026.102891_bib0015","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of Human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102891_bib0016","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/nri1983","article-title":"Perforin-mediated target-cell death and immune homeostasis","volume":"6","author":"Voskoboinik","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102891_bib0017","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.3390\/cancers13246355","article-title":"Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (NCSCL) treated with immune checkpoint inhibitors (ICIs): a prospective study","volume":"13","author":"Tenuta","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tranon.2026.102891_bib0018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.05.031","article-title":"Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1\/-L1 therapy","volume":"65","author":"Dercle","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102891_bib0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/jcm8040450","article-title":"Association of sarcopenia with and efficacy of anti PD-1\/PD-L1 therapy in non-small-cell lung cancer","volume":"8","author":"Nishioka","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tranon.2026.102891_bib0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jcsm.12538","article-title":"Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma","volume":"11","author":"Chu","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"4 Pt 1","key":"10.1016\/j.tranon.2026.102891_bib0021","first-page":"E628","article-title":"Postexercise net protein synthesis in human muscle from orally administered amino acids","volume":"276","author":"Tipton","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.tranon.2026.102891_bib0022","first-page":"E122","article-title":"An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein","volume":"273","author":"Biolo","year":"1997","journal-title":"Am. J. Physiol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102891_bib0023","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1152\/jappl.2000.88.2.386","article-title":"An oral essential amino acid-carbohydrate supplement enhances muscle protein anabolism after resistance exercise","volume":"88","author":"Rasmussen","year":"2000","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.tranon.2026.102891_bib0024","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/gut.52.10.1479","article-title":"Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial","volume":"52","author":"Fearon","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.tranon.2026.102891_bib0025","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2005.04.5724","article-title":"Double-blind, placebocontrolled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia","volume":"24","author":"Fearon","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102891_bib0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2003.01.101","article-title":"Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia\/cachexia: a double-blind, placebo-controlled study","volume":"21","author":"Bruera","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102891_bib0027","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2004.06.024","article-title":"An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancerassociated wasting: a north central cancer treatment group and national institute of Canada collaborative effort","volume":"22","author":"Jatoi","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102891_bib0028","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.bjc.6601620","article-title":"Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with N-3 fatty acids","volume":"90","author":"Moses","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2026.102891_bib0029","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.clnu.2005.07.002","article-title":"Cancer Cachexia study group. Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer","volume":"24","author":"Bauer","year":"2005","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.tranon.2026.102891_bib0030","article-title":"Bort-Mart\u00ed S. Megestrol acetate for treatment of anorexia-cachexia syndrome","author":"Garcia","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tranon.2026.102891_bib0031","doi-asserted-by":"crossref","first-page":"M165","DOI":"10.1093\/gerona\/58.2.M165","article-title":"Effects of testosterone replacement and\/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial","volume":"58","author":"Lambert","year":"2003","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"3","key":"10.1016\/j.tranon.2026.102891_bib0032","article-title":"Megestrol acetate for treatment of anorexia-cachexia syndrome","volume":"2013","author":"Vicente Ruiz","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.tranon.2026.102891_bib0033","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts:a population-based study","volume":"9","author":"Carla M","year":"2008","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102891_bib0034","first-page":"74","article-title":"Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study","volume":"2","author":"Bruera","year":"1998","journal-title":"Cancer Prev. Control"},{"issue":"2","key":"10.1016\/j.tranon.2026.102891_bib0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","article-title":"Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study","volume":"20","author":"Jatoi","year":"2002","journal-title":"J. Clin. Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:30:28Z","timestamp":1791703828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":35,"alternative-id":["S1936523326002287"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102891","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversing sarcopenia with megestrol acetate ameliorates systemic inflammation and improves survival in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102891"}}